Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

You could be waiting a long time for the dividend to catch up to that of higher-paying stocks.

Why Dividend Investors Shouldn't Bother With Thermo Fisher

AbbVie

Abbott Labs

Anthem

Bristol-Myers

Cigna

Johnson & Johnson

Medtronic

Merck

PIMCO Corporate & Income Opportunity Fund

Cohen & Steers Reit And Preferred Income Fund Inc

abrdn Life Sciences Investors 

UnitedHealth Group

A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better.

3 Big Dividends, Paying Monthly, For Your Retirement Basea

Con Ed

Hormel Foods

Kimberly-Clark

McCormick

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

With stock indexes near record highs, it's worth grabbing some defensive holdings now. Here are seven safe stocks to buy.

7 Best Stocks to Buy if You Don't Like to Take Chances

Applied Materials

Activision Blizzard

Bank of New York Mellon

Cintas Corp

Domino's Pizza

Goldman Sachs

Home Depot

Humana

Intercontinental Exchange

JPMorgan Chase & Co

Lockheed Martin

Lowe's

Lam Research

Mastercard

MarketAxess Holdings

Morgan Stanley

Northrop Grumman

Northern Trust

Roper Technologies

Charles Schwab

Sherwin-Williams

SS&C Technologies Hlds

T. Rowe Price Group

Tractor Supply

Texas Instruments

Visa

ViacomCBS

I present 30 High Growth Dividend Stocks for consideration in August 2021. There are 4 new stocks on this month's watchlist, 3 with dividend yields above 2%.

High Growth Dividend Stocks For August 2021

Thermo Fisher Scientific (TMO) CEO, Marc Casper on Q2 2021 Results - Earnings Call Transcript

Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View

Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.63% and 5.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher Scientific (TMO) Tops Q2 Earnings and Revenue Estimates

Shares of Thermo Fisher Scientific (NYSE:TMO) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share rose 43.96% over the past year to $5.60, which beat the estimate of $5.49.

Thermo Fisher Scientific: Q2 Earnings Insights

Thermo Fisher Scientific Inc's (NYSE: TMO) Q2 revenues grew 34% Y/Y to $9.3 billion, beating the consensus of $8.8 billion. Organic revenue growth from the base business was 27%.

Thermo Fisher's Q2 Earnings Beat Expectations; Raises FY21 Outlook

WALTHAM, Mass., July 27, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced its commitment to achieve net-zero carbon emissions by 2050.

Thermo Fisher Scientific Commits to Achieve Net-Zero Carbon Emissions by 2050

With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

Amgen

Fidelity MSCI Health Care ETF

Gilead Sciences

iShares U.S. Healthcare ETF

Pfizer

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Healthcare ETFs in Focus as Q2 Earnings Unfold

Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth

Thermo Fisher's (TMO) new instrument enables high-resolution images of nanoparticles and beam-sensitive materials to be obtained from a commercially available desktop SEM.

Thermo Fisher (TMO) Advances Customer Research With New Launch

Alcoa

Comerica

Shell Midstream Partners LP

Helix Energy Solutions Group

Medallia Inc

Renewable Energy Group

Wayfair

With the trading day past the halfway mark, the major averages were pulling back despite a strong start to the day.

Alcoa, Comerica, Shell Midstream, Thermo Fisher and More Friday Afternoon Analyst Calls

Thermo Fisher's (TMO) new facility will manufacture materials that are essential for production of plasmid-based therapies and vaccines.

Thermo Fisher (TMO) to Meet Plasmid DNA Demand With New Facility

WALTHAM, Mass., July 15, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif.

Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California

News for Thermo Fisher Scientific Stock (TMO)